Nano-Polymeric Biomaterials Used in Cancer Drug Delivery by Knox, Meagan L. & Schuppel, Matthew W.
 
Nano-Polymeric Biomaterials Used in Cancer Drug Delivery 
 
Meagan L. Knox# and Matthew W. Schuppel# 
 
Stephenson School of Biomedical Engineering, University of Oklahoma, Norman OK 73071 
 
Abstract 
 Cancer drug delivery therapy has become an increasingly researched field.  Between the 
understanding of how nanomedicine can be used in cancer therapies, and the needs of a polymer to deliver 
drugs to targeted organs and cells, nanopolymers are being used in this field to increase the efficacy of 
cancer treatments.  To use an effective treatment, there must first be an understanding of the inefficiencies 
of the conventional approaches such as chemotherapy, radiotherapy, and surgery.  The properties of an 
efficient nanopolymer can then be addressed in its degradation properties, bioactivity, bioavailability, 
biocompatibility, and targeting mechanisms.  The use of polymeric micelles, carbon nanotubes, liposomes, 
dendrimers, etc. have been used in nanomedicine as effective polymers for drug delivery.  Modifying these 
polymers as in PLGA, PEG, and other inorganic polymers has created an environment optimal for loading 
drugs and incorporating them into cancerous cells.  Testing the use of these polymers has decreased the 
toxicity of the drug therapy and increased the efficiency of nanopolymer treatments.  The discussion of the 
use of polymers in cancer drug delivery and the types of polymers leads to the conclusion that nanopolymers 
are increasingly being used for cancer therapy and finding significant results in their efficacy.  Increasing 
use of drugs such as paclitaxel loaded into one of the nanopolymers previously mentioned is becoming a 









Drug delivery techniques come in many different forms.  Through the course of medical 
development, drug delivery techniques have evolved and changed creating new and improved forms of 
treating diseases and illnesses such as cancer.  In the realm of cancer drug delivery, there has been 
improvement in the targeting treatments of drug delivery for healing.  To develop new and improved 
delivery techniques, it is important to understand the properties of the materials being used for drug 
delivery.  By manipulating the mechanical properties and understanding the necessities of properties needed 
in the region of the body being targeted, we can develop new techniques for better approaches.  Along with 
mechanical properties, we can manipulate the degradation properties of the material.  In polymers used for 
drug delivery specifically, we strive to use biodegradable biomaterials so the body can break down the 
polymer and use the drug as necessary for treatment.  With the use of biodegradable materials, we also must 
focus on the bioinert or bioactive properties of the polymer itself.  The activity of the polymer on the body 
makes a difference in the ability of the drug activity and the desired treatment.   
 The motivation to understand different nano-polymeric biomaterials used in cancer drug delivery 
stems from the necessity to create more efficient and effective cancer treatments.  Understanding the 
conventional approaches to cancer treatment, as well as the new approaches, gives physicians a better 
chance of treating their patients with greater statistical outcomes from the illness.  With cancer being one 
of the most harmful illnesses to humans in recent centuries, it is essential to find new treatments leading to 
a better chance of survival and remission1.  Cancer functions by targeting essential organs, which is harmful 
to the human body causing treatment to be difficult in targeting the correct region without harming the body 
more2.  To solve this issue, engineering of nano-polymeric biomaterials has been researched to find an 
effective way to deliver drugs to regions of interest without harming other regions of the body or healthy 
cells in that tissue.  Many different nano-polymeric biomaterials are used and researched for their different 




1.1 Biodegradability and Biocompatibility        
When we look into cancer therapies, the common treatments for many years have been the use of 
radiotherapy, surgery, and chemotherapy.  The research into new delivery methods have stemmed from the 
issues with the inability to dissect all the cancer cells in a surgery, and the toxic side effects of chemo and 
radiation therapies.  Due to the issues that are caused with the conventional approaches to cancer drug 
therapy, new technologies and medicines have been developed.  The use of nanomedicine in creating 
polymers such as polymeric micelles, carbon nanotubes, liposomes, dendrimers, and more have created a 
new branch of medicine to treat cancer by using drug delivery in safer and more effective ways.  These new 
polymeric biomaterials used in cancer drug therapy have made treatments more efficient and decreased the 
number of side effects in cancer patients1.  When synthesizing polymers, a component of the research is to 
create a material that is non-toxic.  A byproduct of synthesizing a non-toxic polymer for cancer drug 
delivery is the non-invasive approach of nanoparticles3.  To create this innovative, non-invasive approach 
with nanoparticles, we look into their biocompatibility.  To achieve biocompatibility, polymers are made 
from simple monomers naturally present in the body which can then be excreted creating the non-toxicity 
of the material that is desired for treatments.   
Along with creating biocompatible polymers for cancer drug delivery, biodegradability is an 
important factor.  To achieve biocompatibility in the polymer used for drug delivery and provide bioactive 
molecules to the targeted region of the body, degradation properties are essential to understanding the 
polymer.  A biodegradable material experiences degradation in in vivo applications while continuing to be 
non-toxic to the patient.  To prevent an inflammatory response, the biodegradation can be approached by 
enzymatic or non-enzymatic pathways.  Both natural and synthetic polymers can be created for optimal 
biocompatibility and biodegradation including, hyaluronan, albumin, polyethylene glycol (PEG), 
polylactide acid (PLA), and more.  Biodegradable nanoparticles are key for drug delivery due to their 
mechanisms for controlled-release systems (CRS).  For non-toxicity and biocompatibility in a 
biodegradable polymer, it is essential that the properties of the materials cross barriers in the body such as 
the blood-brain barrier or ophthalmic barrier with molecule concentration control over time.  The drug can 
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be administered through direct diffusion or from dissociation of the polymer into its monomeric 
components.  The polymer can control the timing of the drug release into its targeted organ or tissue as well 
as produce the monomeric components, which are the components of degradation, and ultimately be 
excreted.  Different stimuli such as pH, temperature, etc. can have an effect on the degradation of the 
polymer.  Creating pH-switchable polymers have been a novel approach to cancer drug delivery where they 
can change pH depending on the region of the body they encounter and ultimately lead to optimal 
degradation and compatibility in the desired region3.  In cancer drug therapy, the conventional approaches 
lead to side effects and toxicity that are not ideal for healing.  By using polymeric nanoparticles in cancer 
drug therapy, we can reduce those effects with different approaches such as encapsulating known cancer 
drugs with polymers and targeting the cancer cells while considering their degradation and compatibility 
techniques.    
1.2 Targeting Strategies 
Targeting of cancer cells can be done in two ways, passive targeting and active targeting.  Passive 
targeting uses the release of the drug by using the tumor tissue that passes molecules with either convective 
or passive diffusion in the cells and interstitial space in the tissue.  In most cancers, there is a process called 
enhanced permeation and retention effect (EPR), which is essentially exploited in the drug delivery 
processes using cancer drugs.  The enhanced permeation and retention effect is a mechanism where non-
targeted drugs with a high molecular weight are accumulated in tissues with increased vascular 
permeability, such as cancer tissues4.  This then works to release the molecules in the interstitial space due 
to the permeability of the endothelial lining in the blood vessels from inflammation or hypoxia.  Active 
targeting on the other hand is done through binding nanoparticles to the surface of antibodies, proteins, or 
peptides in specific locations.  The location that is chosen for binding is found from an overexpression of 
that receptor in the tumor cells3.  By understanding the cancer cells and the receptors present, passive and 
active targeting methods can be used for effective localization of the bioactive agent, cancer drug, making 
the therapy less toxic on healthy tissue, and efficient cancer therapy.  Both passive and active targeting are 
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shown in figure 1, where we can distinguish between passive diffusion of the drug and active targeting of 
receptors on the cancer tumors.  
  
Figure 1. 
Shows the difference between passive and active targeting of drugs in cancer therapy with polymeric 
nanoparticles in cancer tumor tissue3. 
 
2. Background 
2.1 Conventional Approaches 
 The conventional approaches, being chemotherapy and radiotherapy, have been widely used over 
the last few centuries in cancer treatment.  Chemotherapy, Radiotherapy, and surgical removal of cancer 
tissue is used to target the active cancer cells with a mass removal and the hope of curing the illness.  
Chemotherapy uses chemicals to kill cells that have a fast proliferation rate; however, it cannot specifically 
target cancer cells over healthy cells leading to toxicity in the body5.  The toxins in some chemotherapies 
can be found in the body to interact with DNA leading to altered protein synthesis which can be mutagenic 
or carcinogenic potentially causing harm while targeting the cancer6.  Radiotherapy uses high doses of 
radiation to kill the cancer cells; however, radiotherapy as well as chemotherapy cannot target the specific 
cancer cells over healthy cells leading to a diminished immune system and possibly toxicity in the body7.  
Surgical removal of cancer tissue is the removal of the cancerous tissue that is contained to one area of the 
body.  This method is flawed because it is oftentimes unable to remove many areas of cancerous tissue or 
all of the cancer cells leaving some to proliferate continuing the illness.  While these techniques are common 
and relatively easy to use, they cause significant harm to the body and do not always eliminate the cancer 
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cells without depleting essential immune cells needed in the body.  This leads us to research and develop 
an understanding of nano-based cancer treatments for a more effective and efficient treatment targeting 
cancer cells while leaving healthy immune cells to help attack the illness. 
2.2 Nano-based Approaches  
In nano-based cancer therapy approaches, polymers are one of the main materials used as well as 
one of the more heavily researched materials. Polymeric materials are preferred because they have potential 
for surface modifications with chemical transformations, excellent pharmacokinetic control, and provide a 
good place to trap and deliver therapeutic agents. There are many methods of polymeric drug delivery 
including, but not limited to, polymeric micelles, nanoparticles, dendrimers, and vesicles. Different 
methods are used to achieve specific results in terms of loading optimization, biodegradability, 
bioavailability, and optimal release control. 
   2.2.1 Polymeric Materials: Polymeric Micelles 
One of the nanocarriers that is widely used for drug delivery in cancer therapy is polymeric micelles 
or PMs. PMs are nanocarriers that are formed by spontaneous arrangement of amphiphilic block 
copolymers in aqueous solutions9. Polymeric micelles have been used to carry drugs to tumors. These 
nanoparticles have a hydrophobic core and a hydrophilic shell where the hydrophobic drugs are loaded into 
the core to improve the solubility of these drugs. PM carriers provide many advantages including ease of 
preparation and ability to be customized to fit specific needs for a particular target. To improve drug uptake 
for specific cells, targeting ligands can be attached to polymeric micelles helping to prevent side effects 
from off-target cell uptake.  One example of a PM that is used currently is Genexol-PM, it is made up of 
polyethylene glycol (PEG) - polylactide. This PM carries chemotherapeutic paclitaxel to tumors and is 
accepted for use in the United States.   
 Polymeric micelles are customizable from the start. Different intermolecular forces that drive the 
micelle formation can cause the block copolymer micelles to form different categories. There are polyion 
complex micelles, hydrophobically assembled amphiphilic micelles, and metal complexion rooted micelles. 
The hydrophobic assembled micelles form the hydrophobic core and hydrophilic shell previously 
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mentioned. PMs can also come in a variety of shapes which include rods, vesicles, spheres, and tubules. 
The shape is dependent on the length of the hydrophilic and hydrophobic block as well as the environment 
the solvent provides. The morphology of the micelles is shown to have a major impact on the 
pharmacokinetic properties of micelles. An example of this is that worm-like filomicelles have about ten 
times longer circulation time in comparison to spherical micelles made of similar material10.  
 Polyethylene glycol (PEG) is the most used hydrophilic part of the micelles for drug delivery 
purposes. PEG has a molecular weight of 2-15 KDa and is neutrally charged, water soluble, and nontoxic 
making it an ideal molecule for the body. By using PEG, a hydrophilic protein corona is formed upon the 
surface of the PMs which helps to remove interactions with unintended components of the blood and 
improve circulation time of the drug delivery system. This allows more of the drug to reach its intended 
target. Although PEG is by far the most widely used, there are other molecules, such as 
polyvinylpyrrolidone (PVP)11 and poly(N-isopropylacrylamide) (pNIPAM)12, that can be used for the 
hydrophilic section of PMs.  
 When constructing the hydrophobic domain of the PMs, biocompatibility and biodegradability are 
two important factors to consider. Most systems use polymers such as poly(lactic acid) PLA, poly(L-
Lysine) PLL, or poly(beta-amino ester) for this hydrophobic region. To be considered biodegradable, 
polyesters and polyamides must undergo enzyme catalyzed hydrolysis in vivo.  
2.2.2 Polymeric Materials: Dendrimers  
 Dendrimers are another method of polymeric drug delivery used in cancer nano therapy. 
Dendrimers are branched nanostructures that have an inner core. Both the inner core and outer layer carry 
the intended drug electrostatically or via covalent bonding. The most common macromolecules used in this 
area of drug delivery are polyamidoamine (PAMAM), polypropyleneimine, and polyaryl ether13. These 
particles used for dendrimer drug delivery can range in size anywhere between 1 and 100nm but typically 
tend to be less than 10nm.  
The importance and specialty of dendrimers is based on the heavily branched and globular 
structure, its defined molecular weight, and ability to control surface functionality all increasing the ability 
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for them to transport and successfully deliver drugs. The versatility of dendrimers allows these molecules 
to deliver both hydrophilic and hydrophobic drugs14.  
Dendrimers have many advantages including increased solubility and stability, increased half-life, 
and permeability of drugs. They also can deliver a wide variety of drugs, have targeting abilities, reduced 
macrophage uptake, and reduced side effects due to more accurate targeting.  There are limitations to 
dendrimers as well. These include inefficient releasing of the desired drug once at location, unstable 
hydrophobic drug loading, and toxicity due to their size.  
Despite the promising research, dendrimer-based cancer therapy drug delivery systems, where a 
defined dosage is required, is still not available for general medical use. This is mainly due to the lack of 
ability to synthesize large quantities of clinical grade purity for clinical trials15.  That being said, there are 
many ongoing studies and trials that show promising results, and it can be expected for dendrimers as a 
drug delivery method to be further researched. 
 
3. Recent Advances 
3.1 Docetaxel Nanotechnology 
Docetaxel is used in cancer treatments as an antitumor drug.  The use of docetaxel with polymeric 
biomaterials for drug delivery has increased the efficacy of drug delivery in cancer treatments.  Combining 
docetaxel with different nano-polymers has led to the research in nanomedicine on the efficacy of new 
methods for cancer drug delivery.  Docetaxel is an anticancer drug that is widely used in cancer therapy for 
breast, gastric, ovarian, prostate, and non-benign lung cancers.  This drug is used by interacting with cellular 
microtubule networks key for mitotic and interphase functions, which contributes to great efficacy in 
antitumor and anti-angiogenic mechanisms.  Docetaxel can be combined with each of the following nano 
polymeric drug carriers to attack cancer and tumor cells within the body and create an overall more effective 




3.2 Polymeric nanocarriers  
Polymers are found in either organic, inorganic, or microbial fermentation polymer forms such as proteins, 
peptides, polylactic acid (PLA), poly (lactic-co-glycolic-acid) (PLGA), and polyhydroxybutyrate 
respectively17.  Polymers can be modified with liposomes, dendrimers, and micelles for a more effective 
drug delivery system.  A combination of organic and inorganic polymers such as a chitosan-coated PLGA 
nanoparticle have been used in treatment to deliver proteins to an organ of interest.  When PLA 
nanoparticles are coated in PEG, their stability is increased while exposed to the body, which aids in the 
transport of the drug to the targeted regions of the body.  A type of polymer used in drug delivery is a 
nanosponge.  Nanosponges are created from biocompatible and biodegradable PLGA nanoparticles fused 
with erythrocyte membrane vesicles.  These polymers are made of hyper-cross-linked cyclodextrins, which 
creates a porous nanoparticle ideal for drug transport.  The structure of nanosponges gives them the ability 
to absorb toxins and other harmful material from tumor cells18.  The structure and shape along with the 
negative surface charge of the nanosponge makes them ideal for holding molecules of many sizes for 
targeting drug resistant cells and increasing effectiveness of chemotherapy treatments19.  Nanosponges are 
an ideal cancer drug polymer because they can permeate an erythrocyte membrane to target abnormal 
cancer cells while decreasing toxicity due to the elimination process through the liver.  Another polymer 
used in cancer drug delivery is an albumin nanoparticle bound to paclitaxel or a derivative of docetaxel.  
This polymer is commonly used in breast, lung, and pancreatic cancers.  The albumin nanoparticle polymer 
is an effective option for cancer treatments among other polymers because it has increased water solubility 
and decreasing toxicity.  There are many polymer nanoparticles in clinical trials, including the albumin 
nanoparticle, which are more effective than the conventional approaches by increasing circulation time of 
the drug and activity within the cancerous tissue.  Many different polymers are used in cancer drug delivery 
for more effective treatments as the solubility, circulation time, biocompatibility, and stability are increased 






One nano polymer that can be used for cancer drug delivery is a dendrimer.  A dendrimer is a 
macromolecule with a core, an interior-branching-dendritic structure, and an exterior surface. The drugs 
used for treatment can be attached to the dendrimer in its area of compatible solubility for the most effective 
treatment within the body.   
Dendrimers can be used in drug delivery to increase aqueous solubility, pharmacodynamics, and 
pharmacokinetics.  Dendrimers are different from linear polymers in the sense that they are more 
controllable and have surfaces that can be modified.  Passive targeting can be used for drug release in 
dendrimers with many molecules attached to its surface.  Due to the structure, functional groups, and 
properties of dendrimers, they can be modified to a specific structure as needed for drug delivery.  A 
dendrimer with surface functionalized polyamidoamine (PAMAM) and carboxyl groups immobilize DNA 
aptamers which targets cancer cells for high efficacy.  When PEGylated, a PAMAM dendrimer has also 
been used in cancer therapy by targeting antitumor activity.  Another modified dendrimer used in cancer 
drug delivery is a methotrexate conjugated PEGylated poly-L-ysine dendrimer, which has been used for 
treatment in fibrosarcoma tumors.  Dendrimers are biocompatible with the body and can be excreted easily 
which makes them an efficient material to use for drug therapy than the conventional treatments used in 
cancer treatments as well as comparatively with other nanotechnologies.  The PAMAM dendrimer is more 
effective and biocompatible than a dendrimer on its own because of the amino groups attached to the surface 
allowing them to circulate longer in the body.  Dendrimers can be excreted from the body as readily as 
molecules such as growth factors and peptides.  Although dendrimers are an effective nanotechnology for 
cancer therapy, they are cytotoxic to normal cells in the body as that is a less desirable property in cancer 
treatment.  However, modifications to dendrimers make the efficacy of them greater than the conventional 
methods in some cases.  Dendrimers can also be used in conjunction with other molecules such as 
liposomes, nanoparticles, and carbon nanotubes for modified solubility in drug delivery.  Each of these 
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modifications increases the biocompatibility and efficacy for use with cancer drug delivery and 
treatments18.    
3.4 PLGA 
 PLGA (poly-d,l-lactide-co-glycolide) is a widely used biodegradable polymeric material in 
nanomedicine and nano-cancer therapy because it undergoes hydrolysis in the body to result in lactic acid 
and glycolic acid. The body can naturally and effectively deal with these two monomers resulting in very 
little toxicity levels when using PLGA for drug delivery. 
Acetone dissolved polymer is added drop by drop to an aqueous phase causing the organic phase 
to evaporate under reduced pressure. There are many different uses for PLGA nanoparticles including 
development of: nanovaccines, gene delivery system, nano-antagin, growth factor, and more. Many factors 
affect the release and effectiveness of the nanomedicines made from PLGA including: surface modification, 
particle size, drug entrapment methods, and molecular weight. Due to the acidic nature of PLGA, it is not 
used by itself for drugs or bioactive molecules21. There are, however, PLGA nanoparticle blends that allow 
for them to be used for these purposes including blending it with pectin, chitosan, and alginate.  
PLGA has been approved for human use, nanomedicine, and nanotherapy by the USFDA22. PLGA 
is widely used for entrapment of anticancer drugs in cancer nanotherapy. The surface of a PLGA 
nanoparticle can be modified to target specific tumors or tissues in the body. PLGA nanoparticles of a larger 
size are best used for multifunctional imaging and probes that include entrapped cancer drugs, release, and 
targeting in a single nanoparticle system23. Although, the efficiency of these nanoparticles are not perfect 
and other methods are used to improve the performance. The properties of the nanoparticles (shape, size, 
surface morphology, etc) can be altered to increase the efficiency.  
To increase the delivery efficiency of cancer related drugs, PLGA nanoparticles are used to 
encapsulate them. 9-Nitrocamptothecin (9-NC) is promising in the field of anticancer drugs and provides a 
unique targeting mechanism for the nuclear enzyme topoisomerase-I. Although, the delivery of 9-NC is 
difficult due to its low water solubility and instability at biological pH. PLGA was used to entrap 9-NC by 
nanoprecipitation and this has led to a more than 30% encapsulation efficiency without the loss of 9-MCs 
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anticancer properties24. The delivery efficiency in vivo has also led to a more controlled release of 9-MC. 
Paclitaxel is a drug that causes cell death by disrupting cell division. It is effective against breast, colon, 
ovarian, and carcinoma cancers. Due to its low solubility, it is less effective for cancer treatment even 
though it is a potent anticancer agent. PLGA with vitamin E TPGS has been used to encapsulate paclitaxel 
by solvent evaporation and extraction methods for controlled release. This combination has shown a decent 
amount of activity and much faster administration than other delivery methods25. The release shows a 50% 
burst release in the first 24 hours of administration with a slow release for one month in vivo. It is shown 
that encapsulating paclitaxel in PLGA-TPGS nanoparticles strongly increases delivery efficiency and blood 
circulation time. An even more improved method of PLGA-TPGS drug delivery system is discussed in the 
Polymeric Micelles section. Cisplatin is another anticancer drug that crosslinks DNA molecules in ways 
that interfere with cell division by mitosis. It is a very potent anticancer agent but has limited clinical use 
due to its toxicity in health issues. Targeted delivery of  cisplatin to only cancerous cells would help reduce 
toxicity levels and improve drug efficiency.  Encapsulating cisplatin in PLGA nanoparticles by double 
emulsion methods have shown increased drug resistance in the blood via intravenous administration26. In 
addition, at the targeted site of the PLGA-mPEG nanoparticles loaded with cisplatin, there has been fast 
degradation and controlled release of the cisplatin preventing tumor growth.  
3.5 Polymeric Micelles  
 Pluronics®, otherwise known as poloxamers, are a nonionic block copolymer which has a structure 
resembling an A-B-A set up. They are made up of hydrophobic propylene oxide (PO) fragments, as well as 
hydrophilic ethylene oxide (EO) branches. These poloxamers have a central poly(propylene oxide) (PPO) 
block which forms the hydrophobic core in the micelle where the drug is carried. This core is encompassed 
on both sides by two hydrophilic chains of poly(ethylene oxides) (PEO) which forms the hydrophilic corona 
shell of the micelle. Ultimately, this structure looks like PEO-PPO-PEO which is shown below.  
Poloxamers have also been used as a protective coating for nanocarriers to improve circulation time 
in the blood for more effective targeting. The central PPO block is the point that is anchored to the surface 
of the nanocarrier via hydrophobic interactions. The pluronic class of polymers, or poloxamers, is approved 
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by the FDA as an inactive ingredient, a substance added that has no pharmacological effect28. Thus, 
poloxamer has been recognized as a polymer that can be used for an effective drug delivery method. The 
downside to pluronics is that they can be unstable and form aggregates. That being said, poloxamers have 
the sought after therapeutic property of multiple drug resistance, which is widely used in nano-polymer 
anticancer therapy. In light of this, poloxamers have been largely used in the formation of polymeric 
micelles to deliver chemotherapeutic drugs in cancer therapy.   
Zhao et al. has shown the loading of circumin (Cur), an anticancer agent derived from the Curcuma 
longa plant, in micelles composed of Pluronic P123 and F6829. They saw a highly effective drug entrapment 
and loading rates of 86.93% and 6.99% respectively. They concluded that micelles mixed Pluronic P123 
and F68 serve as a highly potential nanocarrier to improve solubility and biological activity of circumin.  
In another study by Park et al., singlet-oxygen producible polymeric micelles made with Pluronic F127 
conjugated with chlorin e6 were produced30. The PMs were loaded with Doxorubicin, a cytotoxic 
chemotherapy medication, as well to further enhance the anticancer properties of chlorin e6. Resistance to 
Doxorubicin was observed to have lowered without any side-effects thus improving the efficiency of the 
therapy. In another recent study, a micelle-like structure made of poloxamer-methotrexate (MTX) conjugate 
has been developed by Ren et al. as a nanocarrier for methotrexate delivery31. MTX was entrapped to the 
micelle-like structure drug delivery system as well as chemically conjugated.  Poloxamer-methotrexate (p-
MTX) was synthesized by MTX conjugating to poloxamer with an ester bond. The hydrophobic nature of 
the MTX causes it to form the inner core of the p-MTX micelle. The inner core can encapsulate free MTX 
for delivery. The study found that the micelle-like structure causes the MTX to remain in blood circulation 
longer as well as prolonged in vivo resistance time compared to solely free MTX. Poloxamer (427) has also 
been combined with vitamin E TPGS to form micelles for cancer drug delivery systems. These mix micelles 
carry doxorubicin in the core and the surface is covered with folic acid. This is done by introducing folic 
acid conjugated to P407 into the micelles. Introducing TPGS into cancer nanotherapy helps reduce multiple 
drug resistances, provides anticancer properties, and induces apoptosis. Poloxamers have also been shown 
to reverse many drug resistances; another study incorporated PLGA-TPGS/poloxamer 235 in order to 
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overcome many drug resistances in docetaxel resistant human breast cell cancer line 32. The coating of the 
poloxamer on the PLGA-TPGS nanoparticles increased uptake of these nanoparticles in otherwise 
docetaxel resistant MCF-7 human breast cancer cell lines compared to the coatingless PLGA-TPGS 
nanoparticles. Adding the coating caused the nanoparticles to produce a much higher cytotoxicity of loaded 
docetaxel, both in vivo and in vitro, than the coatingless PLGA-TPGA nanoparticles including the clinically 
used docetaxel formulation, Taxotere®.  
 
3.6 Oligomer nanocarriers 
 Chitosan and cyclodextrin are polymeric oligomer nanocarriers that have been studied for the use 
of cancer drug delivery.  The properties of both of these molecules contribute to their biocompatibility and 
efficacy in drug delivery.  Chitosan is a bioactive compound, which can be modified for greater solubility 
in the body and distribution of a desired drug.  Due to the solubility of chitosan in acidic pH environments 
it can degrade and distribute the drug to tumor cells.  The use of chitosan with a cancer drug has less 
cytotoxicity than other forms of polymeric carriers such as dendrimers, which makes it a favorable material 
to use in cancer treatments.  A modified glycol chitosan nanoparticle loaded with docetaxel, a common 
cancer drug, was tested in treatment and found to have high drug loading and drug release efficiency.  
Cyclodextrin is also specifically used in cancer drug delivery due to its ability to interact with an anticancer 
drug and distribute said drug within the body.  Cyclodextrin has a hydrophobic cavity and hydrophilic 
surface which aids in the ability to hold the drug and interact with the body to release the drug when 
necessary.  The use of cyclodextrin in a nanocarrier increases the solubility, stability, and bioavailability of 
the drug into the body within the drug carrier16.  These oligomer nanocarriers are a new and efficient way 
of distributing cancer drugs with the use of organic polymers in conjunction with inorganic polymers to 





3.7 Linear Cyclodextrin Polymer 
A certain type of cyclodextrin used in cancer drug delivery is the linear cyclodextrin polymer.  As 
described above, cyclodextrin is an effective compound for drug delivery due to its structure and ability to 
interact with hydrophobic and hydrophilic environments.  In this experiment, a linear cyclodextrin polymer 
is made by creating a linear high molecular weight cyclodextrin polymer.  This structure is made to increase 
pharmacokinetics, bioavailability, and ultimately increase efficacy of the drug loaded.  The cyclodextrin is 
made into this linear form by a ketal linkage within the molecule, which increases the drug loading 
efficiency and degradation of the polymer.  The ease of degradation of the polymer leads to a decreased 
toxicity which is more effective in drug treatment 33.   
They have shown increased bioavailability and a decreased elimination from the body which 
increases the efficacy of the polymer in drug treatment by increasing circulation time of the drug.  The 
polymer also showed an increase in cellular permeability, which leads to a greater permeation of the drug 
into the targeted region of the body for increased healing thus a lower dose of drug is needed.  The polymer 
also showed a decreased toxicity in the body where negative effects on body weight were limited, which 
also increases the efficacy of the polymer for use in drug delivery33. 
 
Conclusion 
 Polymeric biomaterials used for drug delivery in cancer therapy have evolved significantly in the 
past couple decades. Being a relatively new field, nanotherapeutics lack many FDA approved polymeric 
solutions. Despite liposomes taking the majority of FDA approved nanotherapeutics, polymeric solutions 
are heavily researched due to their ability to be customized to fit anticancer drugs as well as customized to 
improved circulation time in the blood stream leading to more efficient targeting. As described in this paper, 
there are many polymeric nanomaterials used in drug delivery with promising futures such as micelles, 
oligomers, PLGA molecules, dendrimers, and other nanocarriers. These polymeric materials help increase 
bioavailability, permeability, and solubility of many potent anticancer drugs that are otherwise difficult to 
deliver orally.  
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Limitations to the use of nano-polymeric biomaterials in cancer drug delivery include, the inability 
to image and see nanoparticles and the inability to control the release of the drug molecule.   
The inability to image nanoparticles poses a problem when visualizing the distribution of the polymer in 
tissues and organs.  Not all of the organ or tissue can be seen, therefore estimations of the amount of drug 
being released to the cancerous tissue may be taken and vary the actual effectiveness of the polymer in drug 
delivery34.  For the drug to achieve its maximum therapeutic potential, it must be released at the appropriate 
site. The ability to release the drug when it reaches the cancerous cells makes for less dosages and a lower 
dosage amount saving the patient from unnecessary exposure to cytotoxic drugs.  There is a lack of 
knowledge in new ways to modify and change polymers to create more effective ways to deliver cancer 
drugs for treatments.  Future work in this field can consist of studying surface modifications to polymers to 
improve the targeting, circulation time, and release of the anticancer drug.  Overall, more research will 
continue to be done in the field of nanomedicine to create biocompatible polymers with optimal properties 
for the most effective cancer drug therapies.   
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